Merck Expands Swine Vaccine Portfolio

New Ready to Use Vaccine Supports Simplified Swine Disease Protection

Merck Animal Health announces the commercial availability of Circumvent CL, a ready to use vaccine designed to protect pigs three weeks of age and older against Porcine Circovirus Types 2a and 2d and Lawsonia intracellularis. The new vaccine expands the company’s swine health portfolio by offering convenient and targeted disease protection.

Circumvent CL is formulated to simplify herd health programs. The vaccine is provided in a single bottle and does not require mixing or reconstitution. This ready to use design helps reduce preparation time and lowers the risk of handling errors during vaccination.

The new product complements Merck Animal Health’s existing Circumvent vaccine family. It follows the earlier introduction of Circumvent CML, which protects against Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis.

Circumvent CL removes the mycoplasma component to support herds that no longer require vaccination for that disease while still maintaining strong protection against circovirus and Lawsonia.

“Merck Animal Health is committed to delivering innovative, practical solutions that help veterinarians and producers protect herd health while streamlining on-farm operations,” said Brett O’Brien, V.M.D., swine technical services, Merck Animal Health.

“CIRCUMVENT CL provides trusted protection against two of the most significant enteric and systemic disease agents impacting swine production in a ready-to-use formulation. By offering options such as CIRCUMVENT CML and CIRCUMVENT CL, we enable tailored vaccination strategies that simplify vaccine handling and administration.”

Key benefits of Circumvent CL include dual disease protection, ease of use, and flexibility for different herd health needs. The vaccine is designed for pigs three weeks of age and older and supports operations seeking targeted protection without unnecessary components.

Circumvent CL is available in 50 dose and 250 dose presentations. A 500-dose option is expected to become available in the first quarter of 2026. Additional information is available through Merck Animal Health representatives and official company resources.